ea0029p832 | Endocrine tumours and neoplasia | ICEECE2012
Festuccia C.
, Gravina G.
, Marampon F.
, Muzi P.
, Mancini A.
, Piccolella M.
, Negri-Cesi P.
, Motta M.
, Tobolini V.
, Lenzi A.
, Jannini E.
Rationale and aims: Aberrant activation or “reactivation” of androgen receptor in the course of androgen-ablation therapy shows a potential cause for the development of castration-resistant prostate cancer. This study tested the hypothesis that belinostat (PXD101), a potent pan histone deacetylase inhibitor, may potentiate hormonal therapy and prevent onset of castration resistant phenotype Material and Methods. A panel of human prostate cancer (Pca) cells with grade...